The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.
A new genome sequence study suggests sequence conservation is more common in HPV16 isolates from individuals with cancer or pre-cancerous conditions.
A new analysis hints that adenocarcinomas or squamous cell carcinomas may have certain overlapping expression patterns, regardless of the tissue of origin.
Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round.
The clinical diagnostics company will use the funds to invest in a new UK-based manufacturing facility and to accelerate global growth.
Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.
The contract includes a milestone of approval by the Chinese Food and Drug Agency within the next three years.
The test for cervical cancer screening previously received the IVD mark and US Food and Drug Administration approval on the Cobas 4800 system.
The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.
In Nature this week: Plasmodium genomes and evolution, novel developmental disorder loci, and more.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.